Doxorubicin hydrochloride and Gingival bleeding - a phase IV clinical study of FDA data
Summary:
Gingival bleeding is found among people who take Doxorubicin hydrochloride, especially for people who are male, 60+ old, have been taking the drug for 10+ years.
The phase IV clinical study analyzes which people take Doxorubicin hydrochloride and have Gingival bleeding. It is created by eHealthMe based on reports of 18,581 people who have side effects when taking Doxorubicin hydrochloride from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
18,581 people reported to have side effects when taking Doxorubicin hydrochloride.
Among them, 11 people (0.06%) have Gingival bleeding.
What is Doxorubicin hydrochloride?
Doxorubicin hydrochloride has active ingredients of doxorubicin hydrochloride. eHealthMe is studying from 18,617 Doxorubicin hydrochloride users for its effectiveness, alternative drugs and more.
What is Gingival bleeding?
Gingival bleeding (bleeding gums) is found to be associated with 1,723 drugs and 1,013 conditions by eHealthMe.
Number of Doxorubicin hydrochloride and Gingival bleeding reports submitted per year:

Time on Doxorubicin hydrochloride when people have Gingival bleeding *:
- < 1 month: 0.0 %
- 1 - 6 months: 0.0 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 100 %
Gender of people who have Gingival bleeding when taking Doxorubicin hydrochloride *:
- female: 50 %
- male: 50 %
Age of people who have Gingival bleeding when taking Doxorubicin hydrochloride *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 16.67 %
- 30-39: 16.67 %
- 40-49: 16.67 %
- 50-59: 16.67 %
- 60+: 33.33 %
Common drugs people take besides Doxorubicin hydrochloride *:
- Cytarabine: 5 people, 45.45%
- Cyclophosphamide: 5 people, 45.45%
- Vincristine Sulfate: 3 people, 27.27%
- Oncaspar: 2 people, 18.18%
- Dexamethasone: 2 people, 18.18%
- Tamoxifen Citrate: 2 people, 18.18%
- Methotrexate: 2 people, 18.18%
- Zometa: 1 person, 9.09%
- Etoposide: 1 person, 9.09%
- Cytosar-U: 1 person, 9.09%
Common side effects people have besides Gingival bleeding *:
- Thrombocytopenia (decrease of platelets in blood): 5 people, 45.45%
- Fever: 5 people, 45.45%
- Weakness: 4 people, 36.36%
- Anaemia (lack of blood): 4 people, 36.36%
- Diarrhea: 4 people, 36.36%
- Chills (felling of cold): 4 people, 36.36%
- Bleeding Into The Skin: 3 people, 27.27%
- Hyperglycemia (high blood sugar): 3 people, 27.27%
- Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 27.27%
- Nausea (feeling of having an urge to vomit): 3 people, 27.27%
Common conditions people have *:
- T-Cell Lymphoma (a blood cell cancer): 1 person, 9.09%
- Ovarian Cancer Metastatic (cancer of ovary spreads to other organ or parts): 1 person, 9.09%
- Osteoporosis (bones weak and more likely to break): 1 person, 9.09%
- Hepatocellular Carcinoma (liver cancer): 1 person, 9.09%
* Approximation only. Some reports may have incomplete information.
Do you take Doxorubicin hydrochloride and have Gingival bleeding?
Check whether Gingival bleeding is associated with a drug or a conditionHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related studies
How severe was Gingival bleeding and when was it recovered:
Expand to all the drugs that have ingredients of doxorubicin hydrochloride:
Alternative drugs to, pros and cons of Doxorubicin hydrochloride:
- Doxorubicin hydrochloride (18,617 reports)
Common Doxorubicin hydrochloride side effects:
- Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 1,667 reports
- Thrombocytopenia (decrease of platelets in blood): 1,466 reports
- Fever: 1,276 reports
- Nausea and vomiting: 889 reports
- Pneumonia: 861 reports
- Diarrhea: 796 reports
- Fatigue (feeling of tiredness): 754 reports
Browse all side effects of Doxorubicin hydrochloride:
a b c d e f g h i j k l m n o p q r s t u v w x y zGingival bleeding treatments and more:
- Gingival bleeding (14,992 reports)
COVID vaccines that are related to Gingival bleeding:
- Gingival bleeding in Moderna COVID Vaccine
- Gingival bleeding in Pfizer BioNTech Covid Vaccine
- Gingival bleeding in Johnson and Johnson Covid Vaccine
Common drugs associated with Gingival bleeding:
- Fosamax: 1,236 reports
- Xarelto: 1,071 reports
- Aspirin: 1,048 reports
- Zometa: 907 reports
- Prednisone: 809 reports
- Aredia: 566 reports
- Amlodipine: 558 reports
- Methotrexate: 547 reports
- Coumadin: 546 reports
- Omeprazole: 532 reports
All the drugs that are associated with Gingival bleeding:
- Gingival bleeding (1,723 drugs)
Common conditions associated with Gingival bleeding:
- Osteoporosis: 1,109 reports
- Atrial fibrillation/flutter: 1,027 reports
- High blood pressure: 956 reports
- Stroke: 737 reports
- Rheumatoid arthritis: 636 reports
- Multiple myeloma: 436 reports
- Pain: 406 reports
All the conditions that are associated with Gingival bleeding:
- Gingival bleeding (1,013 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on doxorubicin hydrochloride (the active ingredients of Doxorubicin hydrochloride) and Doxorubicin hydrochloride (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Xtandi and Cancer Pain - a second ago
- Xtandi and Neoplasm Progression - 4 seconds ago
- Xtandi and Metastases To Spine - 7 seconds ago
- Xtandi and Pancreatitis - 9 seconds ago
- Xtandi and Neutrophil Count Decreased - 11 seconds ago
- Sleep Paralysis in Viibryd, how severe and when it was recovered? - 13 seconds ago
- Xtandi and Ischaemic Stroke - 15 seconds ago
- Eligard and Respiratory Acidosis - 18 seconds ago
- Eligard and Haemorrhage - 20 seconds ago
- Eligard and Urosepsis - 23 seconds ago